It’s a bit naive to suggest that scrutinising daily price...

It’s a bit naive to suggest that scrutinising daily price movements has no merit in current circumstance. If there has been no major company activity the market might meander independent of fundamentals somewhat, however EYE has just had a very dilutive capital raising, a major development for effectively its only revenue generating product (FDA approval of iTrack Advance) and a big push off the back of it, effectively drawing in institutional investors, retail and sector insiders, quite reasonable to say price discovery is in full swing and on the ground information within the sector wouldn’t be too hard to find for those with means/access. The market more often than not leads the disclosed realities. Similarly of course the company is going to downplay the Medicare threat in communications but until the changes are seen to be rejected they represent a material risk.

That said the large volume today might be on market transaction between two larger parties and help
put a floor on the price, or not!